Publication

Article

Applied Clinical Trials

Applied Clinical Trials-04-01-2025
Volume34
Issue 2

Applied Clinical Trials: April 2025 Interactive Digital Edition

View the Applied Clinical Trials April 2025 issue in an interactive format.

Click here to view our interactive April 2025 issue!

Download Issue PDF
Articles in this issue
Applied Clinical Trials: April 2025 Interactive Digital Edition
Applied Clinical Trials: April 2025 Interactive Digital Edition
What’s Next for DEI?
What’s Next for DEI?
The Impact of DEI Ban On Clinical Research Ecosystem
The Impact of DEI Ban On Clinical Research Ecosystem
Tapping the Patient Voice as a Strategic Differentiator
Tapping the Patient Voice as a Strategic Differentiator
Benchmarking Risks Across Therapeutic Areas
Benchmarking Risks Across Therapeutic Areas
Scaling eSource-Enabled Clinical Trials: Hospital Perspectives
Scaling eSource-Enabled Clinical Trials: Hospital Perspectives

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer
August 26th 2025

Phase I/II RAINFOL-01 Trial Results Lead to FDA Breakthrough Designation for Genmab’s Rina-S for Advanced Endometrial Cancer

Don Tracy, Associate Editor
ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains
August 26th 2025

ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains

Andy Studna, Senior Editor
© JHVEPhoto - © JHVEPhoto - stock.adobe.com
August 26th 2025

FDA Expands Transparency With Daily Adverse Event Reporting

Andy Studna, Senior Editor
ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials
August 26th 2025

ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials

Andy Studna, Senior Editor
Dynavax Technologies’ Investigational Shingles Vaccine Achieves Complete Antibody Response in Phase I/II Shingles Trial
August 26th 2025

Dynavax Technologies’ Investigational Shingles Vaccine Achieves Complete Antibody Response in Phase I/II Shingles Trial

Don Tracy, Associate Editor
© WESTOCK - © WESTOCK - stock.adobe.com
August 26th 2025

Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research

Andy Studna, Senior Editor
© 2025 MJH Life Sciences

All rights reserved.